Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
You may also be interested in...
India’s Wockhardt has announced its first profit in three years and says a restructuring plan will be carried out soon.
Another day, another report on how to tackle the ever-present problem of antimicrobial resistance and the dearth of new treatment. In its latest assessment of the state of play, the AMR Industry Alliance has come up with some alarming facts and figures – and some ideas for the next steps.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.